Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women

Objective: The aim of this study was to investigate the effectiveness of microdose transdermal 17 beta-estradiol (E-2) therapy in postmenopausal women with moderate to severe vulvovaginal symptoms. Methods: This report is based on a subset of 121 women who reported most bothersome moderate or severe vulvovaginal symptoms at baseline, from a previous randomized, double-blind, placebo-controlled, multicenter study of 425 healthy, symptomatic, postmenopausal women. Recruits had experienced at least 7 moderate or severe hot flushes daily for at least I week or at least 50 moderate or severe hot flushes per week for at least 1 week. Effects on coprimary efficacy variables have been reported previously. Participants received low-dose transdermal E-2 Plus levonorgestrel (n = 43; nominal delivery 0.023 mg/d E-2/0.0075 mg/d levonorgestrel), microdose E-2 (n = 42; nominal delivery 0.014 mg/d), or placebo (n = 36) for 12 weeks. Secondary efficacy variables reported herein include mean change from baseline in vaginal pH and vaginal maturation index, the proportion of women with symptoms of vulvar and vaginal atrophy at baseline and week 12, and the proportion of women with moderate-to-severe symptoms of vulvar and vaginal atrophy. Results: Microdose transdermal E-2 treatment was associated with a consistent benefit versus placebo in women with vulvovaginal atrophy. There was a statistically significant difference between both E-2 versus placebo for changes in vaginal pH and vaginal maturation index. Conclusions: Microdose transdermal E-2 offers a useful addition to the therapeutic armamentarium for postmenopausal women in whom vulvovaginal symptoms are particularly troublesome.